Daré Bioscience (DARE) Competitors $2.96 -0.01 (-0.37%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends DARE vs. ORMP, VTYX, CRBU, GALT, TCRX, MIST, IMUX, VIGL, XBIT, and BDTXShould you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Oramed Pharmaceuticals (ORMP), Ventyx Biosciences (VTYX), Caribou Biosciences (CRBU), Galectin Therapeutics (GALT), TScan Therapeutics (TCRX), Milestone Pharmaceuticals (MIST), Immunic (IMUX), Vigil Neuroscience (VIGL), XBiotech (XBIT), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Daré Bioscience vs. Oramed Pharmaceuticals Ventyx Biosciences Caribou Biosciences Galectin Therapeutics TScan Therapeutics Milestone Pharmaceuticals Immunic Vigil Neuroscience XBiotech Black Diamond Therapeutics Daré Bioscience (NASDAQ:DARE) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Do analysts rate DARE or ORMP? Daré Bioscience currently has a consensus target price of $24.00, indicating a potential upside of 712.18%. Given Daré Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Daré Bioscience is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daré Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community prefer DARE or ORMP? Daré Bioscience received 38 more outperform votes than Oramed Pharmaceuticals when rated by MarketBeat users. Likewise, 73.31% of users gave Daré Bioscience an outperform vote while only 72.50% of users gave Oramed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformDaré BioscienceOutperform Votes35773.31% Underperform Votes13026.69% Oramed PharmaceuticalsOutperform Votes31972.50% Underperform Votes12127.50% Which has more volatility & risk, DARE or ORMP? Daré Bioscience has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Which has stronger valuation & earnings, DARE or ORMP? Oramed Pharmaceuticals has lower revenue, but higher earnings than Daré Bioscience. Daré Bioscience is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaré Bioscience$1.88M13.67-$30.16M-$0.59-5.01Oramed Pharmaceuticals$1.34M70.40$5.53M$0.1121.27 Do institutionals and insiders hold more shares of DARE or ORMP? 6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 4.0% of Daré Bioscience shares are held by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor DARE or ORMP? In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Daré Bioscience. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 0 mentions for Daré Bioscience. Oramed Pharmaceuticals' average media sentiment score of 1.12 beat Daré Bioscience's score of 1.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Daré Bioscience Positive Oramed Pharmaceuticals Positive Is DARE or ORMP more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to Daré Bioscience's net margin of -191.65%. Daré Bioscience's return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Daré Bioscience-191.65% N/A -18.98% Oramed Pharmaceuticals N/A -7.27%-6.20% SummaryOramed Pharmaceuticals beats Daré Bioscience on 11 of the 18 factors compared between the two stocks. Remove Ads Get Daré Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDaré BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.71M$7.07B$5.72B$8.06BDividend YieldN/A2.77%4.41%4.09%P/E Ratio-5.006.2824.4919.16Price / Sales13.67232.29400.2387.70Price / CashN/A65.6738.1134.64Price / Book-4.846.566.844.33Net Income-$30.16M$141.52M$3.19B$247.05M7 Day Performance-1.50%-0.22%0.21%1.30%1 Month Performance-6.49%-7.98%-0.10%-8.91%1 Year Performance-51.72%-5.19%13.37%4.95% Daré Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDaré Bioscience2.1681 of 5 stars$2.96-0.4%$24.00+711.1%-51.5%$25.71M$1.88M-5.0030Short Interest ↓Positive NewsORMPOramed Pharmaceuticals1.5211 of 5 stars$2.51-2.3%N/A-14.6%$101.18M$1.34M22.8210VTYXVentyx Biosciences2.7087 of 5 stars$1.42-4.7%$10.00+604.2%-82.8%$101.01MN/A-0.6030Gap DownCRBUCaribou Biosciences2.3717 of 5 stars$1.11-4.7%$10.33+835.1%-81.8%$100.06M$11.48M-0.67100Analyst ForecastGALTGalectin Therapeutics1.6985 of 5 stars$1.59-1.9%$11.00+591.8%-26.2%$99.79MN/A-2.189Gap DownTCRXTScan Therapeutics2.6561 of 5 stars$1.86-6.1%$9.20+394.6%-76.7%$99.27M$2.82M-1.75100Gap DownMISTMilestone Pharmaceuticals2.2184 of 5 stars$1.86+1.1%$17.00+814.0%+59.7%$99.19M$1M-2.3030Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeIMUXImmunic2.9372 of 5 stars$1.09-5.2%$12.67+1,062.1%-13.7%$98.19MN/A-0.8970VIGLVigil Neuroscience4.2258 of 5 stars$2.40-4.0%$19.75+722.9%-37.3%$98.11MN/A-1.1740Earnings ReportUpcoming EarningsAnalyst RevisionPositive NewsXBITXBiotech0.5011 of 5 stars$3.20-1.5%N/A-48.4%$97.55M$4.01M-2.96100Earnings ReportGap DownBDTXBlack Diamond Therapeutics3.0135 of 5 stars$1.71-9.0%$14.40+742.1%-64.3%$96.76MN/A-1.2990Analyst ForecastOptions VolumeNews CoveragePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies Oramed Pharmaceuticals Alternatives Ventyx Biosciences Alternatives Caribou Biosciences Alternatives Galectin Therapeutics Alternatives TScan Therapeutics Alternatives Milestone Pharmaceuticals Alternatives Immunic Alternatives Vigil Neuroscience Alternatives XBiotech Alternatives Black Diamond Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DARE) was last updated on 3/19/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daré Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daré Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
